FLFrancesco N. Lauria

Francesco N. Lauria

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesco N. Lauria has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A case of pulmonary tuberculosis presenting as diffuse alveolar haemorrhage: is there a role for anticardiolipin antibodies?

    by Almerico Marruchella, Angela Corpolongo, Chiara Tommasi, Francesco N Lauria, Pasquale Narciso

    Diffuse alveolar haemorrhage (DAH) has been rarely reported in association with pulmonary infections.


  • Open Access

    New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response

    by Ornella Butera, Teresa Chiacchio, Stefania Carrara, Rita Casetti, Valentina Vanini, Serena Meraviglia, Giuliana Guggino, Francesco Dieli, Marco Vecchi, Francesco N Lauria, et al.

    Background: Interferon-gamma (IFN-γ) release assays (IGRAs) were designed to detect latent tuberculosis infection (LTBI). However, discrepancies were found between the tuberculin skin test (TST) and IGRAs results that cannot be attributed to prior Bacille Calmètte Guerin vaccinations. The aim of this study was to evaluate tools for improving LTBI diagnosis by analyzing the IFN-γ response to RD1 proteins in prolonged (long-term response) whole blood tests in those subjects resulting negative to assays such as QuantiFERON-TB Gold In tube (QFT-IT). Methods: The study population included 106 healthy TST+ individuals with suspected LTBI (recent contact of smear-positive TB and homeless) consecutively enrolled. As controls, 13 healthy subjects unexposed to M. tuberculosis (TST-, QFT-IT-) and 29 subjects with cured pulmonary TB were enrolled. IFN-γ whole blood response to RD1 proteins and QFT-IT were evaluated at day 1 post-culture. A prolonged test evaluating long-term IFN-γ response (7-day) to RD1 proteins in diluted whole blood was performed. Results: Among the enrolled TST+ subjects with suspected LTBI, 70/106 (66.0%) responded to QFT-IT and 64/106 (60.3%) to RD1 proteins at day 1. To evaluate whether a prolonged test could improve the detection of LTBI, we set up the test using cured TB patients (with a microbiologically diagnosed past pulmonary disease) who resulted QFT-IT-negative and healthy controls as comparator groups. Using this assay, a statistically significant difference was found between IFN-γ levels in cured TB patients compared to healthy controls (p < 0.006). Based on these data, we constructed a receiver operating characteristic (ROC) curve and we calculated a cut-off. Based on the cut-off value, we found that among the 36 enrolled TST+ subjects with suspected LTBI not responding to QFT-IT, a long term response to RD1 proteins was detected in 11 subjects (30.6%). Conclusion: These results indicate that IFN-γ long-term response to M. tuberculosis RD1 antigens may be used to detect past infection with M. tuberculosis and may help to identify additional individuals with LTBI who resulted negative in the short-term tests. These data may provide useful information for improving immunodiagnostic tests for tuberculosis infection, especially in individuals at high risk for active TB.


  • Open Access

    Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007

    by Simone Lanini, Vincenzo Puro, Francesco N Lauria, Francesco M Fusco, Carla Nisii, Giuseppe Ippolito

    Hepatitis B outbreaks in healthcare settings are still a serious public health concern in high-income countries. To elucidate the most frequent infection pathways and clinical settings involved, we performed a systematic review of hepatitis B virus outbreaks published between 1992 and 2007 within the EU and USA.


    • 1 December 2003
      • p. 35-43

    The impact of nosocomial infections on hospital care costs.

    by F N Lauria, C Angeletti

    Estimating costs due to nosocomial infection (NI) requires the incremental costs associated with NI diagnosis and treatment must be distinguished from those attributable to the management of the original healthcare problems. We carried out a review of the analyses of additional costs resulting from NIs and the evaluation of the methods used to estimate these costs, in order to perform a cost benefit analysis of NI prevention activities. Characteristics of additional costs for main NIs were initially considered. Secondly, a review of methods for estimating the incremental costs was performed. Finally, a cost effectiveness analysis of NI prevention activities was performed. Few studies estimated the incidence of NLs and assessed the economic burden they cause. Investigators generally estimated only direct additional costs. Implicit physician assessment, unmatched group comparison, matched control and appropriateness evaluation protocol (AEP)-based methods are the methodologies used to estimate incremental days of stay due to NIs. Different studies show possible benefits, in terms of health and cost savings, when hospital-acquired infections are prevented. However, there is a need for further studies to evaluate in greater detail the variables related to costs attributable to these infections and to enhance the control strategies. Moreover, a structured surveillance and control program of NI is the single most effective tool for prevention.